A Study of LY3471851 in Participants With Eczema
J1P-MC-KFAD - ClinicalTrials.gov - NCT04081350
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema.
Trial Summary
Age Range
18 - 70 yearsConditions the trial is for
Atopic Dermatitis (Eczema)What the trial is testing?
LY3471851, PlaceboCould I receive a Placebo?
YesEnrollment Goal
48Trial Dates
Dec 4, 2019 - Jun 24, 2022How long will I be in the trial?
The study will last up to 48 weeks and may include up to 23 visits to the study center.Trial Phase
IKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have been diagnosed with eczema for at least 12 months
Participants must have active areas of eczema
Participants must be willing and able to have skin biopsies (small samples of skin removed for testing)
Participants Must Not:
Participants must not have received certain medications that were applied to the skin for eczema within 14 days prior to baseline (Day 1)
Participants must not have received certain oral or injectable medications or light therapy for eczema within 4 weeks prior to baseline
Participants must not have taken the study drug previously
Lilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo